The Lighthouse | 2013 March 07

Lighthouse Stock Tip Update – Amarin Script Sales

By Erik Zimerman On March 7, 2013 · 7 Comments · In The Whiskey Room

A few months back, one of my updates suggested CEL and AMRN as short term/medium term investments. In the case of CEL, the market had overreacted to new competition in the Israeli market and investors with our suggested timing were repaid with an approximate 69% return. In Amarin’s case (Amarin Corporation Plc, NASDAQ: AMRN), though the stock continued to rise after our endorsement, and providing a 30% return shorty thereafter, I suggested holding on to this position still further. Since Amarin’s announcement to “Go it Alone” in launching their Marine indication for Vascepa, and continuous FDA delays in reaching a regulatory exclusivity decision (NCE), Amarin has continued to lose value; now well below our suggested entry point. Some decrease, based on the the uncertainty of smaller companies launching new drugs successively and lack of acquisition or marketing partner (did they know something we did not? or was the CEO simply holding for too high a bid?) was quite logical. In fact, merger speculation had largely helped fuel Amarin’s rapid increase in share price. Though management so far seems to have been more than competent in achieving their goals and milestones they did fail miserably during this period of rapid share value loss in communicating with their investors. This gave fuel [...]

[Continue Reading...]

S	M	T	W	T	F	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
31

Lighthouse Stock Tip Update – Amarin Script Sales

Recent Posts

Top Posts & Pages

Halls

Archives

Subscribe to Blog via Email

Lighthouse Stock Tip Update – Amarin Script Sales

Recent Posts

Top Posts & Pages

Tags

Halls

Archives

Subscribe to Blog via Email